IPR Issue for Biosimilars

Biosimilars

Biosimilars: potential implications for clinicians

With the expiration of patent protection for several biologics looming, the production of highly similar therapeutic agents has begun to emerge on the pharmaceutical market. These alternative drugs are referred to as biosimilars. Many anticipate that the introduction of these agents will result in a reduction in health care costs, which may create a more affordable biopharmaceutical market and ...

Intellectual Property Rights (ipr)

Thorough tests were conducted on video watermarking systems in 2000 [3]. Audio watermarking tests followed and have recently been completed. The process was lengthy, starting in June 2001 and finishing in July 2003. In summary, a list of technical requirements was made ... Calls For Systems were issued ... systems were received ... and then they were tested. Several members of EBU Project Group...

IPr -recurrence and nilsystems

By a result due to Furstenberg, a homeomorphism T of a compact space is distal if and only if it possesses the property of IP-recurrence, meaning that for any x0 ∈ X, for any open neighborhood U of x0, and for any sequence (ni) in Z, the set RU (x0) = {n ∈ Z : T x0 ∈ U} has a non-trivial intersection with the set of finite sums {ni1 +ni2 + · · ·+nis : i1 < i2 < . . . < is, s ∈ N}. We show that ...

Biosimilars: new promise for reducing healthcare costs

After much anticipation, approval of the first U.S. biosimilar medications may be around the corner. Biosimilars hold the promise of reducing healthcare spending by offering lower-cost alternatives to highpriced biologic drugs. Biosimilars are not generic versions of existing biologics, however. Generic medications contain an active ingredient identical to that in the reference (‘‘brandname’’) ...